• 1.

    Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2017;13(4):265–9.

    Article 

    Google Scholar
     

  • 2.

    Caparello C, Meijer LL, Garajova I, et al. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987–7005.

    CAS 
    Article 

    Google Scholar
     

  • 3.

    Hashimoto Y, Takahashi H, Ohno I, et al. Clinical outcomes of gemcitabine plus nab-paclitaxel (GnP) in initially diagnosed locally advanced pancreatic cancer. J Clin Oncol. 2018;36(4 Suppl):407.

    Article 

    Google Scholar
     

  • 4.

    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article 

    Google Scholar
     

  • 5.

    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    CAS 
    Article 

    Google Scholar
     

  • 6.

    Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–10.

    CAS 
    Article 

    Google Scholar
     

  • 7.

    Holland MM, Bhutiani N, Kruse EJ, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB (Oxford). 2019;21(8):1024–31.

    Article 

    Google Scholar
     

  • 8.

    Huang KW, Yang PC, Pua U, et al. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. J Surg Oncol. 2018;118(1):31–6.

    CAS 
    Article 

    Google Scholar
     

  • 9.

    Martin RC II, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262(3):486–94; discussion 492–94.

    Article 

    Google Scholar
     

  • 10.

    Martin RC II, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am College Surg. 2012;215(3):361–9.

    Article 

    Google Scholar
     

  • 11.

    Bhutiani N, Agle S, Li Y, Li S, Martin RC II. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J Surg Oncol. 2016;114(2):181–6.

    CAS 
    Article 

    Google Scholar
     

  • 12.

    Pandit H, Tinney JP, Li Y, et al. Utilizing contrast-enhanced ultrasound imaging for evaluating fatty liver disease progression in pre-clinical mouse models. Ultrasound Med Biol. 2019;45(2):549–57.

    Article 

    Google Scholar
     

  • 13.

    Cui G, Martin RC, Liu X, et al. Serological biomarkers associate ultrasound characteristics of steatohepatitis in mice with liver cancer. Nutr Metabol. 2018;15:71.

    Article 

    Google Scholar
     

  • 14.

    Erstad DJ, Sojoodi M, Taylor MS, et al. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Dis Models Mech. 2018;11(7):dmm034793.

    Article 

    Google Scholar
     

  • 15.

    Nywening TM, Belt BA, Cullinan DR, et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67(6):1112–3.

    CAS 
    Article 

    Google Scholar
     

  • 16.

    Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol. 2018;44(10):1619–23.

    Article 

    Google Scholar
     

  • 17.

    Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9.

    Article 

    Google Scholar
     

  • 18.

    Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.

    CAS 
    Article 

    Google Scholar
     

  • 19.

    Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial neoadjuvant FOLFIRINOX and chemoradiotherapy for resectable pancreatic adenocarcinoma. JAMA Oncol. 2018;4(7):963–9.

    Article 

    Google Scholar
     

  • 20.

    Zhao J, Wen X, Tian L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10(1):899.

    Article 

    Google Scholar
     

  • 21.

    Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg. 2004;8(8):1072–8.

    Article 

    Google Scholar
     

  • 22.

    Ikezawa K, Hikita H, Shigekawa M, et al. Increased Bcl-xL expression in pancreatic neoplasia promotes carcinogenesis by inhibiting senescence and apoptosis. Cell Mol Gastroenterol Hepatol. 2017;4(1):185–200.

    Article 

    Google Scholar
     

  • 23.

    Kasai S, Sasaki T, Watanabe A, et al. Bcl-2/Bcl-x(L) inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett. 2017;14(1):903–8.

    CAS 
    Article 

    Google Scholar
     

  • 24.

    Daniels C, Rubinsky B. Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues. J Biomech. Eng. 2009;131(7):071006.

    Article 

    Google Scholar
     

  • 25.

    Ireland L, Santos A, Ahmed MS, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76(23):6851–63.

    CAS 
    Article 

    Google Scholar
     

  • 26.

    Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.

    CAS 
    PubMed 

    Google Scholar
     

  • 27.

    Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.

    CAS 
    Article 

    Google Scholar
     

  • 28.

    Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 1998;25(2 Suppl 5):4–12.

    CAS 
    PubMed 

    Google Scholar
     

  • 29.

    Villalona-Calero MA, Xu Y. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13(12):1841–51.

    Article 

    Google Scholar
     



  • Source link